Pfizer Sees Positive 26-Week Data for Potential Biosimilar To Rituximab
Pfizer (PFE) is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of more than 80 products.
At the American Society of Hematology Annual Meeting, Pfizer announced that its REFLECTIONS B328-06 study had met its primary endpoint of overall response rate at Week 26 of the 52-week study. The study is a comparative safety and efficacy study of the PF-05280586 versus Rituxan/MabThera. The study is to be used for patients with indolent follicular lymphoma.
The study has shown comparable safety and efficacy at the 26-week point of the 52-week study.
The FDA has accepted PF-05280586 for review.
“It is encouraging to see new data supporting a potential rituximab Biosimilar. If approved this may help provide a more cost-effective treatment option and expand access for patients and physicians. The data presented today will help us understand the nuances of the medicine without the confounding influence of additional concurrent treatments.” -Dr. Jeff Sharman, medical director, US Oncology Hematology Research
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!